Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses how we can improve outcomes after transplant in acute myeloid leukemia (AML). Prof. Craddock touches upon a range of avenues, including measurable residual disease, the optimal conditioning regimen and novel therapies. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Improving outcomes after transplant in AML
